EGEllen M. Ginzler

Ellen M. Ginzler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ellen M. Ginzler has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The lupus damage index revision program: Results from the item generation and reduction phases

    by Burak Kundakci, Megan R W Barber, Ann E Clarke, Sindhu R Johnson, Anselm Mak, Hermine I Brunner, Murat Inanc, Rosalind Ramsey-Goldman, Guillermo Ruiz-Irastorza, Ellen M Ginzler, et al.

    Objective: A data-driven and expert/patient consensus-based project to develop a revised Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) is under way supported by SLICC, ACR, and the Lupus Foundation of America. Our objective is to report the item generation and reduction phase results for a revised SDI. Methods: Item generation included a literature review by literature review groups and a Delphi exercise of international systemic lupus erythematosus experts and patients. Item reduction involved Delphi rounds in which items with a median appropriateness score of ≤ 4 of 9 were excluded. A 14-member item reduction committee assessed remaining items and removed those that did not reflect the damage construct, were rare, or were not feasible to assess. The clinical domain groups then refined the remaining items and their definitions. Results: The Delphi panel included 146 individuals from 35 countries. The Delphi exercise nominated 2256 items, and the literature review identified 117 items. After removing redundancies, 226 candidate items remained. Subsequent Delphi rounds, followed by review by the item reduction committee and clinical domain groups, resulted in 39 items across 13 domains. Eleven items from the original SDI, including proteinuria and cranial neuropathy, were removed and several new items were proposed, including growth failure/reduced final height and adrenal insufficiency. Severity-based subitems are proposed for 17 items (43.6%). Conclusion: This data-driven and expert/patient consensus-based process has proposed 39 candidate items, some with subitems, and definitions for a revised SDI. Weighting of items and subitems is underway to develop a clinical scoring system.

  • Open Access

    Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus

    by Eugene Krustev, John G Hanly, Ricky Chin, Katherine A Buhler, Murray B Urowitz, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sánchez-Guerrero, Sasha Bernatsky, et al.

    Background Cranial neuropathies (CN) are a rare neuropsychiatric SLE (NPSLE) manifestation. Previous studies reported that antibodies to the kinesin family member 20B (KIF20B) (anti-KIF20B) protein were associated with idiopathic ataxia and CN. We assessed anti-KIF20B as a potential biomarker for NPSLE in an international SLE inception cohort. Methods Individuals fulfilling the revised 1997 American College of Rheumatology (ACR) SLE classification criteria were enrolled from 31 centres from 1999 to 2011 and followed annually in the Systemic Lupus Erythematosus International Collaborating Clinics inception cohort. Anti-KIF20B testing was performed on baseline (within 15 months of diagnosis or first annual visit) samples using an addressable laser bead immunoassay. Logistic regression (penalised maximum likelihood and adjusting for confounding variables) examined the association between anti-KIF20B and NPSLE manifestations (1999 ACR case definitions), including CN, occurring over the first 5 years of follow-up. Results Of the 1827 enrolled cohort members, baseline serum and 5 years of follow-up data were available on 795 patients who were included in this study: 29.8% were anti-KIF20B-positive, 88.7% female, and 52.1% White. The frequency of anti-KIF20B positivity differed only for those with CN (n=10) versus without CN (n=785) (70.0% vs 29.3%; OR 5.2, 95% CI 1.4, 18.5). Compared with patients without CN, patients with CN were more likely to fulfil the ACR haematological (90.0% vs 66.1%; difference 23.9%, 95% CI 5.0%, 42.8%) and ANA (100% vs 95.7%; difference 4.3%, 95% CI 2.9%, 5.8%) criteria. In the multivariate analysis adjusting for age at baseline, female, White race and ethnicity, and ACR haematological and ANA criteria, anti-KIF20B positivity remained associated with CN (OR 5.2, 95% CI 1.4, 19.1). Conclusion Anti-KIF20B is a potential biomarker for SLE-related CN. Further studies are needed to examine how autoantibodies against KIF20B, which is variably expressed in a variety of neurological cells, contribute to disease pathogenesis.


  • Open Access

    Collaboration for the Management of Hydroxychloroquine

    by James T. Rosenbaum, Karen H. Costenbader, Julianna Desmarais, Ellen M. Ginzler, Nicole Fett, Susan M. Goodman, James R. O’dEll, Gabriela Schmajuk, Victoria P. Werth, Ronald B. Melles, et al.


  • Open Access

    Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus

    by Daniel J. Wallace, Ellen M. Ginzler, Joan T. Merrill, Richard A. Furie, William Stohl, W. Winn Chatham, Arthur Weinstein, James D. McKay, W. Joseph McCune, Michelle Petri, et al.

    Objective: To investigate the long‐term safety and efficacy of intravenous (IV) belimumab plus standard of care (SOC) therapy for systemic lupus erythematosus (SLE) in patients with active, autoantibody‐positive SLE.Methods: The study was designed as a multicenter, open‐label, continuation study of IV belimumab given every 4 weeks in conjunction with SOC therapy in patients with SLE who completed a phase II, double‐blind study. Adverse events (AEs) and laboratory data were monitored from the first belimumab dose (in either study) until 24 weeks after the final dose. Efficacy assessments included SLE Responder Index (SRI) and flare index scores (each assessed at 16‐week intervals) and glucocorticoid use (assessed at 4‐week intervals).Results: Of the 476 patients in the parent study, 298 (62.6%) entered the continuation study, of whom 96 (32.2%) remained in the study. Patients received belimumab for up to 13 years (median duration of exposure 3,334.0 days [range 260–4,332 days], total belimumab exposure 2,294 patient‐years, median number of infusions 115.5 [range 7–155]). The percentage of patients with AEs each year remained stable or decreased. Normal serum IgG levels were maintained in the majority of patients over the study, and the rate of infections remained stable. The percentage of patients who achieved an SRI response increased from 32.8% (year 1) to 75.6% of those remaining on treatment at year 12. The glucocorticoid dose was decreased in patients who had been receiving >7.5 mg/day at baseline.Conclusion: This study is the longest to date to assess belimumab treatment in patients with SLE in clinical trials. Belimumab was well tolerated with no new safety concerns, and efficacy was maintained in patients who continued the study. For patients who initially exhibited a satisfactory response to belimumab, the treatment continues to be well tolerated and provides long‐term disease control.


  • SAT0192 Post-hoc analysis to assess effect of belimumab in patients on mycophenolate mofetil with renal manifestations at baseline

    by F. Houssiau, M.A. Dooley, C. Aranow, D. D'CRuz, A. Askanase, D.A. Roth, S. Cooper, Z.J. Zhong, W. Freimuth, E.M. Ginzler

    Background Mycophenolate mofetil (MMF) is an accepted induction and maintenance therapy in lupus nephritis. In the phase 3 BLISS-52 (NCT00424476) and BLISS-76 (NCT00410384) SLE trials, patients on MMF at baseline (BL) treated with belimumab + standard therapy demonstrated an enhanced treatment differential in the composite SLE Responder Index endpoint: 24.6%. 36.1% and 52.2% with placebo (standard therapy alone), and belimumab 1 and 10 mg/kg, respectively. Objectives To determine whether there was additional benefit from belimumab in patients with renal involvement receiving MMF in the BLISS trials. Methods Patients with BL renal manifestations treated with MMF ± belimumab were assessed for improvement in renal parameters (by reduction in BILAG A/B/C scores and SELENA-SLEDAI). Results 189 patients were on MMF at BL. 29.6% had ≥1 renal SELENA-SLEDAI item; 15.3% had BILAG renal A/B and 40.2% had renal C scores; 40.2% had proteinuria >0.5 g/24 h. Renal SELENA-SLEDAI improvement was seen by wk 52 in 27.8%, 52.6%, and 63.2% of patients with placebo, and belimumab 1 and 10 mg/kg, respectively (table). Assessment of BILAG renal improvement (requiring BL A/B scores) was difficult due to the small numbers of patients: 3/8 (37.5%), 4/9 (44.4%), and 7/12 (58.3%) improved with placebo, and belimumab 1 and 10 mg/kg, respectively; of patients with BL BILAG A/B/C, the corresponding numbers were 7/35 (20.0%),11/34 (32.4%), and 11/36 (30.6%). Table 1. Improvement in SELENA-SLEDAI renal organ system and items Conclusions The BLISS trials excluded patients with severe active lupus nephritis. The sample size for this analysis was reduced by restricting analysis to patients taking MMF at BL. The data, however, suggest that belimumab may provide additional benefit in patients with SLE with continued renal activity despite treatment with MMF. Disclosure of Interest F. Houssiau Consultant for: GlaxoSmithKline/Human Genome Sciences, M. Dooley Grant/Research support from: GlaxoSmithKline/Human Genome Sciences, Consultant for: GlaxoSmithKline/Human Genome Sciences, C. Aranow Grant/Research support from: GlaxoSmithKline/Human Genome Sciences, Consultant for: GlaxoSmithKline/Human Genome Sciences, D. D’Cruz Consultant for: GlaxoSmithKline/Human Genome Sciences, A. Askanase: None Declared, D. Roth Shareholder of: GlaxoSmithKline, Employee of: GlaxoSmithKline, S. Cooper Shareholder of: Human Genome Sciences, Employee of: Human Genome Sciences, Z. Zhong Shareholder of: Human Genome Sciences, Employee of: Human Genome Sciences, W. Freimuth Shareholder of: Human Genome Sciences, Employee of: Human Genome Sciences, E. Ginzler Grant/Research support from: GlaxoSmithKline/Human Genome Sciences, Consultant for: GlaxoSmithKline/Human Genome Sciences